Aquestive Therapeutics: Analysts Increase Price Target to $10.51
ByAinvest
Monday, Nov 17, 2025 5:55 pm ET1min read
AQST--
Aquestive Therapeutics' (AQST) average one-year price target has been revised to $10.51/share, a 14.80% increase from the prior estimate of $9.15/share. This is based on analysts' targets ranging from $8.08 to $15.75/share. The average target represents a 94.92% increase from the latest closing price of $5.39/share. The number of funds reporting positions in AQST has increased to 251, with institutional ownership rising by 33.78% to 70,713K shares. The put/call ratio of AQST is 0.26, indicating a bullish outlook.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet